Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05495178 |
Other study ID # |
hepatobiliary manifestations |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
June 1, 2013 |
Est. completion date |
June 1, 2022 |
Study information
Verified date |
October 2022 |
Source |
Zagazig University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Several studies using different methodological approach have revealed incomplete, old and
conflicting data on the course of hepatobiliary manifestations after surgery. authors
conducted a prospective observational study to evaluate the role of LRP on the course of
hepatobiliary manifestations for a better knowledge of these manifestations that is necessary
to improve their management.also, to evaluate the role of surgery on prevention of liver
damage from progression of the disease.
Description:
Inflammatory bowel disease (IBD) prevalence is expected to reach 1% of the population in many
regions over the next decade. despite the fact that the primary clinical manifestations of
IBD are centred in the gastrointestinal tract, 25-40% of IBD patients develop at least one
extraintestinal manifestation (EIM).
Hepatobiliary manifestations constitute one of the most common EIMs in IBD . Hepatobiliary
manifestations are much more commonly associated with ulcerative colitis (UC) and include
primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), fatty liver,
cholelithiasis, primary biliary cholangitis, portal vein thrombosis, and hepatic abscess.
Most UC patients can be managed medically, but a minority requires proctocolectomy. Two-stage
laparoscopic proctocolectomy (LPC) with ileal pouch-anal anastomosis (IPAA) is a cure for
colitis, but its effect on hepatobiliary diseases is controversial.